PSI CRO AG’s Post

With over 5k patients enrolled in 25+ studies, across 40 countries and 800 site activations, IQVIA’s expertise in radiopharmaceutical clinical trials can help you to drive innovation and bring treatments to patients, faster. As demand to treat patients with Radioligand therapy (RLT) grows, you need an experienced partner to help you navigate this challenging clinical development landscape. Find out more. https://bit.ly/3Ygvbfm #clinicalstudies #clinicaltrials #clinicaldevelopment

Need you all to provide feedback to CMS by 9/11 regarding Nuc Med reimbursement for radiopharmaceuticals. This is not FIND Act, but along the lines of what we have been asking for to support growth, R&D and patient access in MI. See link below, 49577 page 26 I am providing feedback and support for either: (1) paying separately for diagnostic radiopharmaceuticals with per-day costs above the OPPS drug packaging threshold of $140; (2) establishing a specific per-day cost threshold that may be greater or less than the OPPS drug packaging threshold; https://lnkd.in/gaK8Ys-k

Engaging ClinOne early on in your patient and site strategies can yield great results. #clinicaltrials #clinicalresearch #patientengagement #patientexperience #hcpengagement

Rejuvenate Biomed : positive results from Phase 1b clinical trial with RJx-01 in sarcopenia https://lnkd.in/dNrAij3U #clinicaltrial #sarcopenia #pharma Rejuvenate Biomed

Heart failure (HF) treatment is cumbersome and targets for intervention are multifactorial. Our standard of care for HFrEF has emerged with pharmaceutical options, device therapies, and lifestyle modifications. The association between ejection fraction (EF) and clinical outcomes has been well established. For those patients with HFpEF, the current guidance for medical therapy may not be enough and we should look beyond EF. Advanced practice providers are an integral part of the team approach in treating heart failure and should be abreast of various ways to improve patient outcomes. 💓 Read the full article at https://heyor.ca/L5Zg1r

To sell and market YOUR products, services or ideology irrespective of your profession, Trade or businesses of intention or motive ; even if it is politics or political ideology, winning the election, press, mass-media / journalism or arms ammunitions with allied launching vehicles; air, naval, land , marine or submarine defensive or offensive or whatever else like education, realestate, finance, insurance, pharmaceuticals, etc. ! In fact, nothing is difficult or impossible to accomplish or achieve if driven by utmost honesty, truthfulness, commitment and be performance or results oriented; it doesn't matter whether your issue is aggressive, offensive or defensive but must be free of lying, hypocrisy and double standard diplomacy! Just put yourselves at the place, position, state or status of clients, / prospects, audiences, stakeholders and identify products and services of your feelings, ideology, demand, needs, choice , likes and dislikes at present and in future and accordingly customize or generalize; design or redesign, define or redefine , invent or innovate those products and services being the ever sustainable strategy and master key to unlock the door to reach your goal faster and first than your competitors concerned!

Xeris Pharmaceuticals® Medical Affairs is excited to share a clinical update with an upcoming Poster Presentation at #ENDO2024. Come and view our Poster (bit.ly/SAT-085) on June 1, 2024, Effects of Levoketoconazole on 24-hour Mean UFC (mUFC) in the SONICS Study: Relation to Baseline mUFC in Adults with Cushing’s Syndrome: a Post-hoc Analysis.

Explore Novotech's latest whitepaper, which highlights recent advancements and market insights in radiopharmaceuticals. #DidYouKnow that over the past five years, global clinical trials in the radiopharmaceutical sector have surged by 96%, led by North America at 42%, followed by the Asia-Pacific region at 28% and Europe at 26%? For more information, download our latest whitepaper- https://lnkd.in/d9B7wXuA #Radiopharmaceuticals #ClinicalTrials #Novotech

Texas Society of Hospital Pharmacists (TSHP) Round Rock, TX April 5-7, 2024 Located deep in the heart of Texas Hill Country, Round Rock is rich in history, abundant in local culture, and the host to this year’s Texas Society of Hospital Pharmacists.  The Meitheal team will be in attendance, so stop by our booth to learn more about how we are bringing stabilization to Generics and expanding into Biologics and Biosimilars. By doing so, we continue to simplify access to life-changing medicine, for the common good. Think sustainability, think Meitheal. #HospitalPharmacy #Pharma #Generics #Biosimilars